All News

Article

Predictors and Outcomes in Systemic Sclerosis

EurekAlert! Jun 13, 2025

The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will fulfil the 2013 ACR/EULAR SSc criteria within 5 years.

Article

Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Mrinalini Dey, MBBChir, MA(Hons) Cantab., MRCP, FHEA Jun 12, 2025

Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic options for patients with autoimmune ILDs.

🌍Patients w RMDs across 🇫🇷🇳🇱🇨🇭🇹🇷 face different barriers to physical activity: 💶Cost =barrier in 🇳🇱 ⛈️Weather =barrier in 🇹🇷 🧑‍⚕️HCP support =key in 🇫🇷 🏃Active transport & knowledge =enablers in 🇨🇭 Tailored physical activity interventions needed. @RheumNow #EULAR2025 #OP0382-HPR https://t.co/lk7fwDHDe7

https://x.com/DrMiniDey/status/1933463606147899562/photo/1

Can RZB deliver in real-world early PsA? 💥 9-month results say yes: ✅ Dactylitis gone in 79% ✅ Enthesitis in 90% ✅ 97% MDs & 88% pts satisfied Early intervention may pay off. Abstract POS0304 @RheumNow #EULAR2025

What is new in SpA? ‼️nomenclature change: 🚫AS≠ Ankylosing spondylitis ✅AS= Axial spondyloarthritis -Helena Marzo-Ortega at #EULAR2025 @RheumNow

About #Multidisciplinarity ... Dr Ihsane Hmamouchi talking about Multidisciplinary Approach to Migrant #Rheumatology Care #quotes #EULAR2025 #Invitedspeaker #outofthebox @RheumNow @epirheum https://t.co/RG6xpHejv9

https://x.com/Nellziade/status/1933503623708704963/photo/1

Worth mentioning: the type of monoclonal protein is important for diagnosis. Different diseases with different therapies #EULAR2025 @RheumNow l https://t.co/5bbQnHV6CI

https://x.com/drdavidliew/status/1932790928185700426/photo/1

The great debate: are cannabis and cannabinoids a valid treatment option in patients with rheumatic diseases? A thread 🧵👇🏼 @RheumNow #EULAR2025 https://t.co/KLZN9MvcFy

https://x.com/AurelieRheumo/status/1933167023678464465/photo/1

Even after having things laid out in a great debate, rheumatologists remain unconvinced by medical cannabis #EULAR2025 @RheumNow https://t.co/xMTvngS5N1

https://x.com/drdavidliew/status/1933179631160742222/photo/1

Intraarticular IL-1Ra Gene Therapy in Knee Osteoarthritis In a dose-escalation trial in nine participants, they observed that a single intra-articular injection of the gene product led to an increase in IL-1Ra in the synovial fluid that remained elevated for up to a year. There https://t.co/qi0qHPd06j

#polyrefractory #RA = failed all classes in #rheumatoid #arthritis +inflammatory #arthritis Longer disease duration Late RA Rx +power Doppler in POCUS ⬆️no refractory BMI Fibromyalgia - pain ⬇️SJC, less DAS , rapid X-ray progression #EULAR2025 @RheumNow #D2T #RA https://t.co/1sPwf3Qa3m

Transcranial Stimulation is Effective in Fibromyalgia A randomized, controlled clinical trial in fibromyalgia (FM) has shown the efficacy of transcranial direct current stimulation (A-tDCS) (along with exercise and pain neuroscience education [PNE]), in alleviating the pain. https://t.co/P8SKs3JNEx

🦵🏼💉LOSEIT study: liraglutide led to slight↑ in medial joint space width in knee OA vs placebo (0.22 vs 0.07 mm), but difference not statistically significant (p=0.17). More potent GLP-1RAs may be needed for greater improvement in structural knee OA @RheumNow #EULAR2025 #OP0223

GRAPPA defines : - D2T-PsA (failed ≥3 therapies incl. ≥2 b/tsDMARDs) - CM(complex to manage)-PsA (adds pain, comorbidity, complexity). A needed framework to improve trial design & real-world care. Do these definitions fit your clinic? #OP0175 @RheumNow #EULAR2025 https://t.co/ot1bVLIYLA

https://x.com/JihaRheum/status/1933084357042008555/photo/1

The definition of MAS. MAS is secondary HLH. Other causes of secondary HLH are infections, malignancy and iatrogenic. Georgin-Lavialle S @RheumNow #EULAR2025 https://t.co/CpB78JBlVJ

Clinical Pearl's for #MAS Infections are still the most common cause. Next is malignancy... Then other causes like autoimmunity.. Ask a detailed history ! Sometimes check with the family when the pt can't give history.. #EULAR2025 @RheumNow https://t.co/fepercz5Af

https://x.com/bella_mehta/status/1933133818514259968/photo/1

Age of onset is really important when thinking about #MAS Primary HLH more frequent in pediatric population. But can continue to adulthood. #EULAR2025 @RheumNow https://t.co/J7xmTiQiwr

https://x.com/bella_mehta/status/1933136416894222586/photo/1

MAS can be triggered by infections in VEXAS syndrome. The threshold is reached leading to a hyperinflammatory state Georgin-Lavialle S @rheumnow #EULAR2025 https://t.co/NKLL75rOgP

Age & dose ⬆️ infections in JAKi Not all JAKi are created w equal risk ⁦@RheumNow⁩ ⁦@eular_org⁩ #EULAR2015 ⁦@drdavidliew⁩ #JAKi & #infection https://t.co/F7zLUBuzJR

https://x.com/Janetbirdope/status/1933140984277156104/photo/1

Stabilize the pts with HLH with steroids when still trying to figure out the diagnosis of #HLH/ #MAS Many drugs can be used...but important to balance infection risk with immunosuppression These are critical pts. Be vigilant.. #EULAR2025 @RheumNow https://t.co/id4ae3SWtj

Topics

All News

Predictors and Outcomes in Systemic Sclerosis

Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD

Do you get our email newsletter?